肝手術後に肝臓由来ATPが遠隔心障害を引き起こす仕組みを解明(Tsinghua study reveals how liver-derived ATP triggers remote cardiac injury after hepatic surgery)

ad

2026-07-10 清華大学

清華大学北京清華長庚医院の高志峰教授らは、肝移植や肝切除後に生じる心血管合併症の分子機構を解明した。382例の臨床データ、マウス肝虚血再灌流(HIRI)モデル、心臓免疫細胞のシングルセルRNA解析を統合した結果、虚血・再灌流を受けた肝臓から放出されるATPが血中を介して心臓へ到達し、単球由来心臓マクロファージのP2X7受容体を活性化してNLRP3インフラマソームを誘導し、最終的に心筋細胞のGSDMD依存性ピロトーシス(炎症性細胞死)を引き起こすことを明らかにした。動物実験では、ATP除去やP2X7阻害剤投与により心機能障害が軽減され、アデノシンによるA2A受容体刺激もデキサメタゾンやN-アセチルシステインより高い保護効果を示した。本研究は、肝障害から心障害へ至る「ATP–P2X7/アデノシン–A2A経路」を初めて体系的に示し、周術期の心保護療法やリスク評価の新たな治療標的を提示した。

肝手術後に肝臓由来ATPが遠隔心障害を引き起こす仕組みを解明(Tsinghua study reveals how liver-derived ATP triggers remote cardiac injury after hepatic surgery)
Schematic overview: liver-derived ATP drives remote cardiac injury via macrophage P2X7-NLRP3 inflammasome activation

<関連情報>

肝虚血再灌流由来の循環ATPは、マクロファージインフラマソームの活性化を介して遠隔心臓障害を引き起こす Circulating ATP from hepatic ischemia-reperfusion drives remote cardiac injury via macrophage inflammasome activation

Zheng Zhang, Yi Duan, Fulei Gu, Jinyan Wei, Hongyu Huo, Yuze Wang, Dan Lu, Zhifeng Gao
Pharmacological Research  Available online: 17 June 2026
DOI:https://doi.org/10.1016/j.phrs.2026.108306

Highlights

  • MINS incidence rises from 20.5% to 50% with postoperative liver injury severity.
  • Circulating ATP from ischemic liver is sufficient and necessary for cardiac injury.
  • Macrophage P2X7-NLRP3 inflammasome drives cardiomyocyte pyroptosis after HIRI.
  • Macrophage P2X7 gates cardiomyocyte pyroptosis as the dominant upstream node.
  • Delayed P2X7 blockade up to 3 h post-reperfusion retains cardioprotection.

Abstract

Cardiac complications after major hepatic surgery are frequent, yet how hepatic ischemia-reperfusion injury (HIRI) damages the remote heart is unknown. In 382 hepatectomy patients, the incidence of myocardial injury after noncardiac surgery (MINS) rose from 20.5% to 50% with increasing postoperative liver damage severity (P < 0.0001). In a murine HIRI model, cardiac dysfunction lagged behind hepatic injury; circulating ATP surged within one hour of reperfusion from the ischemic liver and was both sufficient and necessary to drive remote cardiac damage. Extracellular ATP activated the P2X7 receptor on cardiac macrophages, triggering NLRP3 inflammasome assembly and gasdermin D (GSDMD)-dependent cardiomyocyte pyroptosis; siRNA-based dominant-gating co-culture identified macrophage P2X7 as the upstream gating step, with cardiomyocyte-side P2X7 knockdown failing to abrogate downstream pyroptosis. Single-cell profiling traced this program to monocyte-derived macrophages differentiating into inflammatory macrophages, and macrophages amplified hepatocyte-derived ATP into IL-1β-driven cardiomyocyte pyroptosis in vitro. Clodronate-mediated macrophage depletion preserved cardiac function. The selective P2X7 antagonist JNJ-47965567 polarized cardiac macrophages toward an anti-inflammatory phenotype and suppressed NLRP3-GSDMD pyroptosis when administered up to approximately 3 h after reperfusion onset, defining a clinically relevant therapeutic window. Adenosine activated the A2A receptor and attenuated cardiac injury dose-dependently, reversed by SCH-58261, and conferred greater cardiac protection than dexamethasone or N-acetylcysteine. These findings establish cardiac macrophages as amplifiers of liver-derived danger signals and identify the ATP-P2X7/adenosine-A2A purinergic axis as a potential pharmacological target for perioperative cardioprotection.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました